Roche Highlights Lunsumio Data Demonstrating Promise in Earlier Treatment Settings for Both Indolent and Aggressive Lymphomas Roche announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment…
Blueprint Medicines presents long-term AYVAKIT® benefits in indolent and advanced systemic mastocytosis at ASH 2025. Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of…
Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Achieves 74% Disease-Free Survival at One Year in Patients with BCG-Unresponsive, High-Risk, Papillary-Only NMIBC Johnson & Johnson announced today that new data from…
Most Nations Advance Toward Universal Health Coverage, Yet Significant Obstacles Persist, Finds WHO–World Bank Report Since 2000, most countries – across all income levels and regions – have made concurrent…
Biogen and Stoke Present New Data Supporting Zorevunersen’s Disease-Modifying Potential in Dravet Syndrome at AES 2025 Biogen and Stoke Therapeutics, a biotechnology company dedicated to restoring protein expression by harnessing the…
Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain…
Advancing Transplant Innovation with First-of-Its-Kind Insights from Organ Donor-Derived Bone Marrow Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical…
IDE034, a Bispecific Antibody-Drug Conjugate Licensed by Biocytogen to IDEAYA, Secures FDA IND Clearance Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq:…
Egypt Achieves Historic Milestone in Healthcare Sovereignty: Becomes Sixth Nation to Attain Plasma Self-Sufficiency with Grifols Partnership Plasma-derived medicines—a feat made possible through a groundbreaking five-year strategic alliance with Grifols,…
Bayer Launches Phase IIa Clinical Trial of Novel Therapy for Alport Syndrome Bayer has announced the initiation of a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody…
Aetna Accelerates National Strategy to Simplify Healthcare for Providers and Patients Through Innovation, AI, and Integrated Care Models Aetna®, a CVS Health® company today announced significant progress on its ambitious,…
Bristol Myers Squibb’s Breyanzi Becomes First and Only CAR T Cell Therapy Approved by FDA for Relapsed or Refractory Marginal Zone Lymphoma Breyanzi® CD19-directed chimeric antigen receptor (CAR) T cell…